Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-Aventis extends collaboration with Ciphergen
Under the terms of the agreement, Ciphergen will analyze samples using its suite of proteomic solutions, pattern track process, and ProteinChip system. Financial terms were not disclosed. Gail
Under the terms of the agreement, Ciphergen will analyze samples using its suite of proteomic solutions, pattern track process, and ProteinChip system. Financial terms were not disclosed. Gail
The phase I dose escalation study, was conducted in Utrecht, The Netherlands, on 32 healthy male and female volunteers between the ages of 45 and 75. The study
Although the company stressed that it may yet decide to retain the OTC business, which has a portfolio of well known products such as the mouthwash Listerine and
Pfizer’s Mexican arm has agreed to pay Oscient an up-front payment, milestones for attaining certain regulatory and sales goals as well as royalties on future sales. Specific financial
The new formula, which comprises 50% insulin lispro protamine suspension and 50% insulin lispro injection (rDNA origin), is now available in an easy-to-use pen delivery device in the
A priority designation is intended for products that address unmet medical needs. The FDA aims to review applications with such designations within six months of receipt; in this
This application to the European Agency for the Evaluation of Medical Products (EMEA) is the second in a series of submissions aimed at obtaining marketing approvals for telbivudine,
In 2005, Theregen received FDA approval to proceed with a phase I safety trial for patients suffering from this cardiovascular disorder. The product will serve as an adjunct
In the phase IIa dose ranging study, OPT-80/PAR-101 was evaluated in 45 patients with clostridium difficile-associated diarrhea (CDAD). The evaluation included cure rates, relief of symptoms of CDAD,
To achieve this goal the companies will combine Affymetrix’s GeneChip microarray technology with Iconix’s DrugMatrix 640 compound reference database and analysis software. Using such tools, researchers will be